NEJM· Liesbeth Van WesenbeeckFreya RasschaertJohnson & Johnson, Beerse, BelgiumKristen K. PierceUniversity of Vermont College of Medicine, BurlingtonGuillermo Herrera-TaracenaJohnson & Johnson, Horsham, PABeulah P. SabundayoJohns Hopkins Bloomberg School of Public Health, BaltimoreAnnemie BuelensJohnson & Johnson, Beerse, BelgiumPatricia LuttonUniversity of Vermont College of Medicine, BurlingtonVeerle Van EygenJohnson & Johnson, Beerse, BelgiumMegan McKnightJohns Hopkins Bloomberg School of Public Health, BaltimoreKim De ClerckJohnson & Johnson, Beerse, BelgiumIsabel FetterUniversity of Vermont College of Medicine, BurlingtonXi FangJohns Hopkins Bloomberg School of Public Health, BaltimoreNele GoeyvaertsKathleen CallewaertJohnson & Johnson, Beerse, BelgiumSarah SampsonJeffrey MayfieldJohns Hopkins Bloomberg School of Public Health, BaltimoreOliver LenzSandra De MeyerJohnson & Johnson, Beerse, BelgiumThomas N. KakudaJohnson & Johnson, San Diego, CAHelen HeJohns Hopkins Bloomberg School of Public Health, BaltimoreEmérito Amaro-CarambotNational Institute of Allergy and Infectious Diseases, Bethesda, MDRuxandra Draghia-AkliJohnson & Johnson, Spring House, PAMarya CarmolliUniversity of Vermont College of Medicine, BurlingtonMarnix Van LoockJohnson & Johnson, Beerse, BelgiumStephen S. WhiteheadNational Institute of Allergy and Infectious Diseases, Bethesda, MDAnna P. DurbinJohns Hopkins Bloomberg School of Public Health, Baltimore·· 3 天前AI 评分24
每周一次Mosnodenvir在人体感染模型中用于登革热预防
Once-Weekly Mosnodenvir as Dengue Prophylaxis in a Human Infection Model
AI 导读
Mosnodenvir以每周一次的给药方案，在人体感染模型中用于评估登革热预防。现有内容仅包含标题及出版信息，未提供研究设计、样本量、预防效果或安全性结果。
来源：NEJM · nejm.org